NQO1 and head and neck squamous cell carcinoma: Over the last decades, work pioneered by Boothman's group has established β-lapachone (β-lap), a NAD(P)H:quinone oxidoreductase 1 (NQO1) bioactivatable substrate, as a promising cancer therapeutic and radiation sensitizer targeting a broad spectrum of cancers including HNSCC (4–9).